{"id":"https://openalex.org/W2068531968","doi":"https://doi.org/10.2337/diacare.21.9.1462","title":"Troglitazone in Combination With Sulfonylurea Restores Glycemic Control in Patients With Type 2 Diabetes","display_name":"Troglitazone in Combination With Sulfonylurea Restores Glycemic Control in Patients With Type 2 Diabetes","publication_year":1998,"publication_date":"1998-09-01","ids":{"openalex":"https://openalex.org/W2068531968","doi":"https://doi.org/10.2337/diacare.21.9.1462","mag":"2068531968","pmid":"https://pubmed.ncbi.nlm.nih.gov/9727892"},"language":"en","primary_location":{"id":"doi:10.2337/diacare.21.9.1462","doi":"https://doi.org/10.2337/diacare.21.9.1462","is_oa":false,"landing_page_url":"https://doi.org/10.2337/diacare.21.9.1462","pdf_url":null,"source":{"id":"https://openalex.org/S49878492","display_name":"Diabetes Care","issn_l":"0149-5992","issn":["0149-5992","1935-5548"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Care","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069336249","display_name":"Edward S. Horton","orcid":"https://orcid.org/0000-0002-5670-3157","observed_orcids":["https://orcid.org/0000-0002-5670-3157"]},"institutions":[{"id":"https://openalex.org/I1293231726","display_name":"Joslin Diabetes Center","ror":"https://ror.org/0280a3n32","country_code":"US","type":"facility","lineage":["https://openalex.org/I1293231726"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edward S Horton","raw_affiliation_strings":["Joslin Diabetes Center\u2008Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Joslin Diabetes Center\u2008Boston, Massachusetts","institution_ids":["https://openalex.org/I1293231726"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112147147","display_name":"Fred W. Whitehouse","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2803043754","display_name":"Henry Ford Hospital","ror":"https://ror.org/0193sb042","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I154057602","https://openalex.org/I2803043754"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fred Whitehouse","raw_affiliation_strings":["Henry Ford Hospital\u2008Detroit, Michigan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Henry Ford Hospital\u2008Detroit, Michigan","institution_ids":["https://openalex.org/I2803043754"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028526553","display_name":"Mahmoud N. Ghazzi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mahmoud N Ghazzi","raw_affiliation_strings":["Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company\u2008Ann Arbor, Michigan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company\u2008Ann Arbor, Michigan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038220801","display_name":"Tom C. Venable","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tom C Venable","raw_affiliation_strings":["Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company\u2008Ann Arbor, Michigan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company\u2008Ann Arbor, Michigan","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"The Troglitazone Study Group","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"The Troglitazone Study Group","raw_affiliation_strings":["Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company\u2008Ann Arbor, Michigan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company\u2008Ann Arbor, Michigan","institution_ids":[]}]},{"author_position":"last","author":{"id":null,"display_name":"Randall W Whitcomb","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Randall W Whitcomb","raw_affiliation_strings":["Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company\u2008Ann Arbor, Michigan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company\u2008Ann Arbor, Michigan","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":10.5894,"has_fulltext":false,"cited_by_count":137,"citation_normalized_percentile":{"value":0.99073744,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"21","issue":"9","first_page":"1462","last_page":"1469"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.003100000089034438,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/troglitazone","display_name":"troglitazone","score":0.9950000047683716},{"id":"https://openalex.org/keywords/sulfonylureas","display_name":"sulfonylureas","score":0.9390000104904175},{"id":"https://openalex.org/keywords/glibenclamide","display_name":"glibenclamide","score":0.9729999899864197},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.718999981880188},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9819999933242798},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.9959999918937683},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.8539999723434448},{"id":"https://openalex.org/keywords/fasting-serum-glucose","display_name":"fasting serum glucose","score":0.902999997138977},{"id":"https://openalex.org/keywords/ppargamma-agonists","display_name":"PPAR\u03b3 agonists","score":0.8009999990463257},{"id":"https://openalex.org/keywords/insulin","display_name":"insulin","score":0.41100001335144043},{"id":"https://openalex.org/keywords/c-peptide","display_name":"C-peptide","score":0.9950000047683716},{"id":"https://openalex.org/keywords/lipid-effects","display_name":"lipid effects","score":0.6069999933242798},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.953000009059906},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7739999890327454},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.41999998688697815},{"id":"https://openalex.org/keywords/insulin-resistance","display_name":"insulin resistance","score":0.38100001215934753},{"id":"https://openalex.org/keywords/beta-cell-function","display_name":"beta-cell function","score":0.5680000185966492},{"id":"https://openalex.org/keywords/insulin-sensitivity","display_name":"insulin sensitivity","score":0.3230000138282776},{"id":"https://openalex.org/keywords/insulin-secretion","display_name":"insulin secretion","score":0.33799999952316284}],"concepts":[{"id":"https://openalex.org/C2778150266","wikidata":"https://www.wikidata.org/wiki/Q7844989","display_name":"Troglitazone","level":4,"score":0.9502725601196289},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7539177536964417},{"id":"https://openalex.org/C2778854520","wikidata":"https://www.wikidata.org/wiki/Q418776","display_name":"Sulfonylurea","level":3,"score":0.7512534260749817},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7110838294029236},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.6174178123474121},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.5707152485847473},{"id":"https://openalex.org/C2780473172","wikidata":"https://www.wikidata.org/wiki/Q5572518","display_name":"Glycemic","level":3,"score":0.4860732853412628},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4354701042175293},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.41742223501205444},{"id":"https://openalex.org/C187345961","wikidata":"https://www.wikidata.org/wiki/Q419629","display_name":"Peroxisome proliferator-activated receptor","level":3,"score":0.151106059551239},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.12342745065689087}],"mesh":[{"descriptor_ui":"D000077288","descriptor_name":"Troglitazone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002096","descriptor_name":"C-Peptide","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002839","descriptor_name":"Chromans","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002839","descriptor_name":"Chromans","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008055","descriptor_name":"Lipids","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D013453","descriptor_name":"Sulfonylurea Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013453","descriptor_name":"Sulfonylurea Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.2337/diacare.21.9.1462","doi":"https://doi.org/10.2337/diacare.21.9.1462","is_oa":false,"landing_page_url":"https://doi.org/10.2337/diacare.21.9.1462","pdf_url":null,"source":{"id":"https://openalex.org/S49878492","display_name":"Diabetes Care","issn_l":"0149-5992","issn":["0149-5992","1935-5548"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Care","raw_type":"journal-article"},{"id":"pmid:9727892","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9727892","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes care","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1971981454","https://openalex.org/W1985317064","https://openalex.org/W2401881665","https://openalex.org/W1993034883","https://openalex.org/W2144739243","https://openalex.org/W2023447984","https://openalex.org/W2019230478","https://openalex.org/W2015503000","https://openalex.org/W2079368549","https://openalex.org/W2409184971"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"determine":[2],"if":[3],"the":[4,266,271],"combination":[5,249],"of":[6,37,221,250],"troglitazone":[7,58,71,231,251],"(a":[8],"peroxisome":[9],"proliferator-activated":[10],"receptor-gamma":[11],"activator)":[12],"and":[13,72,87,92,131,154,172,184,192,252,259],"sulfonylurea":[14,38,242,253],"will":[15],"provide":[16],"efficacy":[17],"not":[18],"attainable":[19],"by":[20,270],"either":[21],"medication":[22],"alone.":[23],"RESEARCH":[24],"DESIGN":[25],"AND":[26],"METHODS:":[27],"There":[28],"were":[29,49,94,149,213],"552":[30],"patients":[31,157,224],"inadequately":[32,239],"controlled":[33,240],"on":[34,90,99,158,228,241],"maximum":[35],"doses":[36],"who":[39],"participated":[40],"in":[41,208,219],"a":[42,248,261],"52-week":[43],"randomized":[44,50],"active-controlled":[45],"multicenter":[46],"study.":[47],"Patients":[48,98,234],"to":[51,264],"micronized":[52],"glyburide":[53,73],"12":[54,223],"mg":[55,64],"q.d.":[56,65,74],"(G12);":[57],"monotherapy":[59,232],"200,":[60],"400,":[61],"or":[62,69,164,170,177,230],"600":[63],"(T200,":[66],"T400,":[67],"T600);":[68],"combined":[70],"(T200/G12,":[75],"T400/G12,":[76],"T600/G12).":[77],"Efficacy":[78],"measures":[79],"included":[80],"HbA1c,":[81],"fasting":[82],"serum":[83],"glucose":[84],"(FSG),":[85],"insulin,":[86],"C-peptide.":[88],"Effects":[89],"lipids":[91],"safety":[93],"also":[95,150],"assessed.":[96],"RESULTS:":[97],"T600/G12":[100],"had":[101],"significantly":[102,132],"lower":[103,133],"mean":[104,134],"(+/-":[105],"SEM)":[106],"FSG":[107,175],"(9.3":[108],"+/-":[109,113,121,125,137,141],"0.4":[110,122],"mmol/l;":[111,123],"167.4":[112],"6.6":[114],"mg/dl)":[115],"compared":[116,225],"with":[117,152,187,205,226,235,247],"control":[118],"subjects":[119],"(13.7":[120],"246.5":[124],"6.8":[126],"mg/dl;":[127],"P":[128,143],"<":[129,144,163,169,176],"0.0001)":[130],"HbA1c":[135,162,168],"(7.79":[136],"0.2":[138],"vs.":[139],"10.58":[140],"0.18%,":[142],"0.0001).":[145],"Significant":[146],"dose-related":[147],"decreases":[148],"seen":[151],"T200/G12":[153],"T400/G12.":[155],"Among":[156],"T600/G12,":[159],"60%":[160],"achieved":[161,167,174],"=8%,":[165],"42%":[166],"=7%,":[171],"40%":[173],"=7.8":[178],"mmol/l":[179],"(140":[180],"mg/dl).":[181],"Fasting":[182],"insulin":[183],"C-peptide":[185],"decreased":[186],"all":[188],"treatments.":[189,216],"Overall,":[190],"triglycerides":[191],"free":[193],"fatty":[194],"acids":[195],"decreased,":[196],"whereas":[197],"HDL":[198],"cholesterol":[199,202],"increased.":[200],"LDL":[201],"increased":[203],"slightly,":[204],"no":[206],"change":[207],"apolipoprotein":[209],"B.":[210],"Adverse":[211],"events":[212],"similar":[214],"across":[215],"Hypoglycemia":[217],"occurred":[218],"3%":[220],"T600/G":[222],"<1%":[227],"G12":[229],"CONCLUSIONS:":[233],"type":[236],"2":[237],"diabetes":[238],"can":[243],"be":[244],"effectively":[245],"managed":[246],"that":[254],"is":[255],"safe,":[256],"well":[257],"tolerated,":[258],"represents":[260],"new":[262],"approach":[263],"achieving":[265],"glycemic":[267],"targets":[268],"recommended":[269],"American":[272],"Diabetes":[273],"Association.":[274]},"counts_by_year":[{"year":2023,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}